Parameter | Number (%) |
---|---|
Age (years) | |
18– 24 | 7 (50.0) |
25 - 31 | 3 (21,4) |
40 - 60 | 4 (28.6) |
Sex | |
Female | 8 (57.1) |
Male | 6 (42.9) |
Weight (kg) | |
40 - 50 | 5 (35.7) |
51 – 60 | 6 (42.9) |
61 - 80 | 3 (21.4) |
Mean ± SD = 56.4 ± 11.2 | |
Height (cm) | |
150 – 160 | 9 (64.3) |
161 – 170 | 4 (28.6) |
171 – 180 | 1 ( 7.1) |
BMI kg/m 2 | |
17.0 – 22.0 | 8 (57.2) |
22.1 – 27.0 | 5 (35.7) |
27.1 – 32.0 | 1 (7.1) |
Mean ± SD = 21.9 ± 4.0 | |
Creatinine clearance (mg/mL) | |
80 - 110 | 3 (21.4) |
111 - 140 | 6 (42.9) |
141 - 170 | 5 (35.7) |
Albumin g/dL | |
2.0 – 2.6 | 3 (21.4) |
2.7 – 3.3 | 7 (50.0) |
3.4 – 4.0 | 4 (28.6) |
Mean ± SD = 3.0 ± 0.6 | |
Antibiotic given in the previous month? | |
Yes | 5 (35.7) |
No | 9 (64.3) |
Malignancy | |
Lymphoma | 2 (14.3) |
Lymphoid leukemia | 9 (64.3) |
Myeloid leukemia | 3 (21.4) |
Number of neutrophils/mm 3 | |
Range | 0–2380 |
Mean ± SD | 208(603.2) |
Therapy cycles | |
1 – 2 | 6 (42.9) |
3 – 5 | 3(21.4) |
6 - 8 | 5 (35.7) |
FN-associated chemotherapy | |
Hyper-CVAD | 10 (71.4) |
No Hyper-CVAD | 4 (28.6) |